EUVIMEDOpdag EUVIMED
Randomisierte kontrollierte StudieOpen access · CC BY-NC-ND 4.0

Efficacy and safety of topical rosuvastatin & melatonin vs. placebo in patients with mild to moderate plaque psoriasis: A preliminary randomized double‐blinded clinical trial

Farhad Mohammadi, Fatemeh Zare Harofteh, Adeleh Sahebnasagh, Narges Ghaneei, Mohammad Ebrahim Zadeh Ardakani, Fatemeh Saghafi iD

Skin Research and Technology · 2024-04 · 30 (4)

DOI: 10.1111/srt.13689 ↗

At a glance

Randomisierte kontrollierte Studie in Skin Research and Technology, published online on 2024-04-02. Written by Farhad Mohammadi and 5 co-authors. Institution: Department of Pharmaceutics, School of Pharmacy, Shahid Sadoughi University of Medical Sciences and Health Services, Yazd, Iran. Major MEDLINE topics: Melatonin, Psoriasis. Cited 12 times so far (Crossref); 42 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Research and Technology Department of Shahid Sadoughi University of Medical Sciences.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Considering the pathogenesis of psoriasis and also the anti‐oxidant, immunomodulatory, and anti‐inflammatory properties of rosuvastatin and melatonin, the current clinical trial aimed to evaluate the efficacy of topical rosuvastatin and melatonin in patients with mild to moderate psoriasis.

Methods

The current randomized placebo‐controlled clinical trial was conducted using a 3‐arm parallel group included 77 adult patients (≥18 years old) with mild to moderate plaque psoriasis. Patients were randomized into a 1:1:1 ratio to one of three groups to receive one of the three interventions: melatonin cream, 5.0% (w/w), rosuvastatin cream, 5.0% (w/w), or placebo cream with a similar transparent appearance twice a day for 12 weeks. The primary outcome was severity of the disease using Psoriasis Area Severity Index (PASI). The secondary outcomes included the Dermatological Sum Score (DSS) to assess the erythema, scaling, and plaque elevation and the Dermatology Life Quality Index (DLQI). Photographs of the lesions were also taken at the baseline and at different periodic intervals thereafter.

Results

Among 77 randomized patients, 52 (mean (SD) age, 40.67 (10.85) years; 22 (42.30%) men) completed the study. A significant reduction of 45% (mean (SD) of 2.67 (0.98) to 1.74 (1.12)) and 70% (mean (SD) of 2.67 (0.98) to 1.31 (1.13)) in PASI score, and 46% (mean (SD) of 2.91(1.85) to 1.57 (1.11)) and 77% (mean (SD) of 2.91 (1.85) to 0.87 (0.67)) in DSS score on days 30 and 60 with rosuvastatin cream, 5% w/w ( P < 0.001) compared with baseline was observed, respectively. Also a significant decrease of 35% (mean (SD) of 2.67 (0.98) to 1.74 (1.12)) and 51% (mean (SD) of 2.67 (0.98) to 1.31 (1.13)) in PASI score, and 40% (mean (SD) of 5.00 (1.58) to 3.00 (1.76))and 61% (mean (SD) of 5.00 (1.58) to 1.92 (1.71)) in DSS score on days 30 and 60 with melatonin cream, 5% w/w ( P < 0.001) compared with baseline were observed, respectively. In each of the melatonin or rosuvastatin groups, DLQI improved significantly on days 30 ( P < 0.0001) and 60 ( P < 0.001) while the changes in the control group were not significant.

Conclusion

The results of this clinical trial demonstrated that topical melatonin and rosuvastatin diminished the severity of mild to moderate plaque psoriasis with a satisfactory safety profile. Future clinical trials should assess both the long‐term efficacy and safety of melatonin and rosuvastatin creams in larger study populations.

Subjects

MeSH terms (MEDLINE)

MelatoninPsoriasisAdultMaleHumansAdolescentFemaleRosuvastatin CalciumAnti-Inflammatory AgentsTreatment OutcomeSeverity of Illness IndexDouble-Blind Method

Author keywords

clinical trialmelatoninpsoriasisrosuvastatin

Substances

MelatoninRosuvastatin CalciumAnti-Inflammatory Agents

Authors and institutions

  • Department of Pharmaceutics, School of Pharmacy, Shahid Sadoughi University of Medical Sciences and Health Services, Yazd, Iran.
  • Pharmaceutical Sciences Research Center, School of Pharmacy, Student Research Committee, Shahid Sadoughi University of Medical Sciences and Health Services, Yazd, Iran.
  • Department of Internal Medicine, Clinical Research Center, Faculty of Medicine, North Khorasan University of Medical Sciences, Bojnurd, Iran.
  • Department of Dermatology, School of Medicine, Shahid Sadoughi University of Medical Sciences and Health Services, Yazd, Iran.
  • Department of Clinical Pharmacy, School of Pharmacy, Shahid Sadoughi University of Medical Sciences and Health Services, Yazd, Iran.

ORCID profiles: Fatemeh Saghafi

Funding

  • Research and Technology Department of Shahid Sadoughi University of Medical Sciences

Cite

APA

Mohammadi, F., Harofteh, F. Z., Sahebnasagh, A., Ghaneei, N., Ardakani, M. E. Z., & Saghafi, F. (2024). Efficacy and safety of topical rosuvastatin & melatonin vs. placebo in patients with mild to moderate plaque psoriasis: A preliminary randomized double‐blinded clinical trial. Skin Research and Technology, 30(4). https://doi.org/10.1111/srt.13689

Vancouver

Mohammadi F, Harofteh FZ, Sahebnasagh A, Ghaneei N, Ardakani MEZ, Saghafi F. Efficacy and safety of topical rosuvastatin & melatonin vs. placebo in patients with mild to moderate plaque psoriasis: A preliminary randomized double‐blinded clinical trial. Skin Research and Technology. 2024;30(4). doi:10.1111/srt.13689

BibTeX
@article{Mohammadi2024,
  author = {Mohammadi, Farhad and Harofteh, Fatemeh Zare and Sahebnasagh, Adeleh and Ghaneei, Narges and Ardakani, Mohammad Ebrahim Zadeh and Saghafi, Fatemeh},
  title = {Efficacy and safety of topical rosuvastatin & melatonin vs. placebo in patients with mild to moderate plaque psoriasis: A preliminary randomized double‐blinded clinical trial},
  journal = {Skin Research and Technology},
  year = {2024},
  volume = {30},
  number = {4},
  doi = {10.1111/srt.13689}
}
Start for free →